Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.
Presentation & Investor Materials
January 30, 2023
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Recent News Releases
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
Thursday, March 30, 2023 4:30 PM EDT